The Duke CTSA KL2 program provides training and research opportunities for junior investigators that will equip them to:
- Participate in and ultimately lead transdisciplinary research teams that both transcend traditional scientific silos and embrace diverse stakeholder input
- Facilitate advancement of discoveries to their next translational phase
- Represent a more diverse workforce to meet evolving translational science priorities, and
- Leverage partnerships locally, regionally, and nationally to enhance the impact of their discoveries.
CTSA KL2 expects scholars to complete the KL2 program equipped and inspired to become successful, independent investigators, making contributions across the entire spectrum of clinical and translational research. The KL2 has three main components:
- Developing productive and beneficial mentoring relationships
- Completing the core curriculum
- Tailored Didactic Coursework
- Training in Responsible Conduct of Research
- KL2 Scholar Curriculum (Seminar Series and Health Disparities Research Curriculum)
- Successfully conducting a clinical or translational research project
Each scholar can receive up to 3 years of support. The program is ongoing with annual recruitment for new scholars.
ELIGIBILITY. This program is for…
- Junior faculty
- Must have a research or health-professional doctoral degree or its equivalent, i.e., a Doctor of Medicine (MD), MD/PhD, or PhD degree.
- An appointment as a Duke Faculty member is required. An applicant may be in the final year of (postdoc) fellowship but must have a faculty appointment by the start of the KL2 award.
The KL2 program is particularly committed to increasing diversity of the research workforce. Therefore, the program has set a goal that at least 50% of KL2 scholars will be from underrepresented racial and ethnic groups (UREGs). Members of underrepresented groups are encouraged to apply.
For questions, contact email@example.com.
This program was established in 2013 and is housed within the Duke Clinical and Translational Science Institute. This program is currently funded by:
- NIH Clinical and Translational Science Award (CTSA)
Award # UL1TR002553
Principal Investigator: Boulware
For questions about funding and other forms of support for this program, contact:
- Laura Svetkey, MD (firstname.lastname@example.org)
- Kimberly Johnson, MD | Program Director (email@example.com)
- Rasheed Gbadegesin, MBBS, MD | Program Director (Rasheed.firstname.lastname@example.org)